双留置针局部尿激酶溶栓治疗动静脉内瘘血栓1例被引量：1

下载PDF

导出

摘要 1病历资料患者,男,56岁,因规律血液透析2年,左上肢疼痛伴动静脉内瘘搏动消失6 h急诊入院。患者2年前明确诊断慢性肾功能衰竭、3级高血压,行左前臂动静脉（桡动脉头静脉端侧吻合）内瘘形成术,2个月后血肌酐达到887μmol/L,开始规律血液透析,每周3次。

作者朱学研王丹杜冰洋

机构地区吉林省吉林市中心医院肾内科吉林省吉林市中心医院超声科吉林省吉林市中心医院介入科

出处《中国实用医药》 2014年第26期190-191,共2页 China Practical Medicine

关键词动静脉内瘘血栓尿激酶溶栓治疗留置针慢性肾功能衰竭血液透析左上肢疼痛内瘘形成术前臂动静脉

分类号 R692.5 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献9

1Drukker W, Parsons FM, Maher JF. Replacement of renal fuction by dialysis. 2nd ed. Boston, the Hague, Dordrecht: Martinus Nijhoff Publishers, 1983:171-185.
2Schilling JJ, Eiser AR, Sliikin RF, et al. The role of thrombolysis in hemodialysis access occlusion. Am J Kidney Dis, 1987, 10(2):92- 97.
3Zeit RM, Cope C. Failed hemodialysis shunts. One year of experience with aggressive treatment. Radiology, 1985, 154(2):353- 356.
4Mangiarotti G, Canavese C, Thea A, et al. Urokinase treatment for arteriovenous fistulae declotting in dialyzed patients. Nephron, 1984, 36(1):60-64.
5戎殳,叶朝阳,陈静,张斌,梅长林.尿激酶溶栓治疗血液透析患者动静脉内瘘血栓形成[J].中国血液净化,2003,2(9):476-478. 被引量：75
6伦立德,孙红,李伟生,朱晓明,屈国林,陈肇一.大剂量尿激酶溶栓治疗内瘘血栓形成[J].中国血液净化,2002,1(10):12-14. 被引量：15
7陶宏炜,郭恩覃.尿激酶原选择性溶解血栓的实验研究[J].中华整形外科杂志,2000,16(2):96-98. 被引量：39
8宋岩,李冀军,张壹言,李学义,陈凤琨,赵长征,姚凤华,殷培.局部尿激酶溶栓治疗血液透析患者动静脉内瘘血栓疗效及治疗方案探讨[J].中国血液净化,2007,6(11):597-600. 被引量：77
9王玉柱.血液透析自体动静脉内瘘狭窄相关因素分析[J].中国误诊学杂志,2005,5(2):213-215. 被引量：49

二级参考文献41

1伦立德,孙红,李伟生,朱晓明,屈国林,陈肇一.大剂量尿激酶溶栓治疗内瘘血栓形成[J].中国血液净化,2002,1(10):12-14. 被引量：15
2李月红,于仲元,王玉柱,朱军,田松.188例尿毒症病人内瘘成熟影响因素分析[J].中国血液净化,2002,1(2):11-14. 被引量：31
3邢新.无复流现象[J].中华显微外科杂志,1994,17(4):303-305. 被引量：9
4[1]Cynamon J, Pierpont CE. Thrombolysis for the treatment of thrombosed hemodialysis access grafts. Rev Cardiovasc Med, 2002, 3 Suppl 2: S75-82
5[2]Cynamon J, Lakritz PS, Wahl SI, et al. Hemodialysis graft declotting: description of the "lyse and wait" technique. JVIR, 1997, 8: 825-829
6[3]Schon D, Mishler R. Salvage of occluded autologous arteriovenous fistulae. Am J Kidney Dis, 2000, 36(4): 804-810
7[4]Gruber A, Harker LA, Hanson SR, et al. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation, 1991,84(6): 2454-2462
8[5]Sofocleous CT, Cooper SG, Schur I, et al. Retrospective comparison of the amplatz thrombectomy device with modified pulse-spray pharmacomechanical thrombolysis in the treatment of thrombosed hemodialysis access grafts. Radiology, 1999, 213(2): 561-567
9[7]Wall TC, Califf RM, Ellis SG, et al. Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group. J Am Coll Cardiol, 1993, 21(3): 597-603
10[8]Ash S, Weng FL, Berns JS. Complications of percutaneous treatment of thrombosed hemodialysis access grafts. Semin Dial, 2003, 16(3): 257-262